|
| Press Releases |
|
 |
|
| Thursday, August 28, 2025 |
|
|
Hua Medicine Announces 2025 Interim Results |
| Hua Medicine (the 'Company', HKEx: 2552) announced the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2025 (the 'Reporting Period'), as well as the Company's business progress during the first half of the year and future outlook. During the Reporting Period, the commercialization of the Company's core product, HuaTangNing'(dorzagliatin tablets), accelerated. The Company's independent operational capabilities improved significantly. more info >> |
|
| Monday, June 23, 2025 |
|
|
Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined with DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeostasis |
| Hua Medicine ("the Company", stock code: 2552.HK) announced today that the Company presented the latest research results of dorzagliatin, its global first-in-class glucokinase activator (GKA), at the 85th Scientific Sessions of the American Diabetes Association (ADA). more info >> |
|
| Friday, March 28, 2025 |
|
|
Hua Medicine Announces 2024 Annual Results |
| Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announced the audited full-year results of the Company and its subsidiaries for the year ended December 31, 2024 (the "Reporting Period"), along with the Company's business progress in 2024 and future business outlook. more info >> |
|
| Tuesday, March 18, 2025 |
|
|
Dr. Li Chen Honored as A Leading Figure in Shanghai's Industry and Commerce |
| On March 17th, the highly anticipated 7th Commendation and Exchange Conference for the Leading Figures in Shanghai's Industry and Commerce was brought to a successful conclusion. Dr. Li Chen, the founder and CEO of Hua Medicine, was awarded the title of "A Leading Figure in Shanghai's Industry and Commerce" for his outstanding contributions and innovative leadership in the field of biomedicine. more info >> |
|
| Monday, March 3, 2025 |
|
|
Hua Medicine Awarded Shanghai Innovative Enterprise Headquarters |
| On February 27th, the awarding ceremony of the second batch of Shanghai Innovative Enterprise Headquarters was held in Shanghai. Gong Zheng, Deputy Secretary of Shanghai Municipal Party Committee and Mayor of Shanghai, awarded the certificates to 49 innovative enterprise headquarters, and Hua Medicine was among them. more info >> |
|
| Saturday, November 30, 2024 |
|
|
Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate |
| Hua Medicine (the 'Company', HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical trial on its 2nd generation GKA candidate in U.S. at the 9th China BioMed Innovation and Investment Conference (CBIIC). more info >> |
|
|
Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC |
| Hua Medicine (the 'Company', HKEx stock code: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism by which dorzagliatin improves the β-cell glucose sensitivity at the 9th China BioMed Innovation and Investment Conference (CBIIC). more info >> |
|
| Friday, October 25, 2024 |
|
|
Founder of Hua Medicine Dr. Chen Li was awarded the 'C.C. Tan Life Science Industrialization Award' |
| The 17th C.C. Tan Life Science Award ceremony was held at Shenyang Pharmaceutical University on October 9th. Dr. Chen Li, Founder and Chief Executive Officer of Hua Medicine, was awarded the C.C. Tan Life Science Industrialization Award . more info >> |
|
| Friday, August 30, 2024 |
|
|
Hua Medicine Announces 2024 Interim Results |
| Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2024 (the "Reporting Period"), and the Company's business progress for the first half of the year and business outlook. more info >> |
|
| Friday, August 25, 2023 |
|
|
Hua Medicine Announces 2023 Interim Results |
| First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Tianneng Power (00819.HK) Main Business Resilient in the First Half of 2025
Aug 29, 2025 00:20 HKT/SGT
|
|
|
Yunkang Group's 2025 Interim Net Loss Narrows, Demonstrating Strong Operational Resilience
Aug 29, 2025 00:02 HKT/SGT
|
|
|
Digital Shovel Announces Partnership with IREN, Culminating in Completion of Infrastructure Support to 26 Sites
Aug 28, 2025 23:50 HKT/SGT
|
|
|
Global Sports Brand U.S. Polo Assn. to Become Title Sponsor of the Palm Beaches Marathon
Aug 28, 2025 21:00 HKT/SGT
|
|
|
SenseTime Announces 2025 Interim Results
Aug 28, 2025 21:20 JST
|
|
|
China Everbright Limited Announces 2025 Interim Results
Aug 28, 2025 19:45 HKT/SGT
|
|
|
Hong Kong Watch & Clock Fair, Salon de TIME return in September
Aug 28, 2025 20:27 JST
|
|
|
Dynasty's Sales Revenue of Wine Products for the First Half of 2025 Reaches HK$123 Million
Aug 28, 2025 19:24 HKT/SGT
|
|
|
Ausnutria 2025 Interim Results Announcement: Revenue and Profit Maintain Resilient Dual Growth 
Aug 28, 2025 19:09 JST
|
|
|
Genetec reinforces foundation for growth, maintains resilient outlook
Aug 28, 2025 18:08 HKT/SGT
|
|
|
Baguio Green Group (1397.HK) Announces 2025 Interim Results
Aug 28, 2025 19:03 JST
|
|
|
Hua Medicine Announces 2025 Interim Results
Aug 28, 2025 17:07 HKT/SGT
|
|
|
Shoucheng and IAT Join Forces to Drive 'Robotics + Automobiles'
Aug 28, 2025 16:43 HKT/SGT
|
|
|
Sunshine Insurance (6963.HK) Interim Results Released
Aug 28, 2025 16:39 HKT/SGT
|
|
|
Production, Sales and Export Results for July, 2025
Aug 28, 2025 17:36 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
